May 27, 2019
PharmaBiome was recognized as a winner of the 2019 startup competition by the De Vigier Foundation. Supporting startups since 1989, the foundation recognizes and fosters entrepreneurship. This year’s winners were selected out of over 200 applications. Tomas de Wouters accepted the price on behalf of the PharmaBiome team, reflecting the important progress that we are making towards developing microbiome-based therapies for life-changing diseases such as ulcerative colitis, cancer and graft-versus-host disease.
May 19 is World IBD day and we are reminded of our goal to help patients who are suffering from inflammatory bowel disease. Currently there is no cure for these debilitating diseases that change the lives of millions of patients and their close ones around the globe.
At PharmaBiome, we are passionate about the microbiome and its therapeutic potential. Our lead compound is rapidly advancing towards clinical testing in ulcerative colitis. In honor of World IBD day, we have supported video artist Doris Oberneder’s perspective on ‘Real talk about intestinal bacteria – is there hope for a cure to IBD?’. It features Bruno Giardina (President Crohn Colitis Switzerland), Gerhard Rogler (Head of Gastroenterology at Zurich University hospital) and Tomas de Wouters (Co-founder and CEO of Pharmabiome).
PharmaBiome was awarded with the seal of excellence from the European Commission Horizon2020 program. We are proud to receive this recognition of the highly competitive SME Instrument Phase 2 call.
Labiotech together with seasoned biotech entrepreneurs generated a list of some of the most inspiring leaders behind the new generation of biotech companies in Europe. Dr. Tomas de Wouters was announced as one of the Top 10 Young European Biotech Entrepreneurs 2019. https://labiotech.eu/tops/young-european-biotech-entrepreneurs/
Philip Hemme from Labiotech interview Dr. Tomas de Wouters to learn about our path to the clinic and our proprietary approach to functional microbiome therapeutics. Check out the video: https://labiotech.eu/videos/pharmabiome-gut-microbiome-ulcerative-colitis/
PharmaBiome was named as a member of the top 100 Swiss Startups, organized by Venturelab. We are proud of this recognition of the work of our team members and the progress that we are making towards realizing microbiome based therapies. https://www.top100startup.ch
PharmaBiome wins the ETH Spark Award 2018. We are proud to be ETH’s most promising invention filed for patent in 2017. https://www.ethz.ch/en/industry-and-society/techoffer/spark-award/2018.html
PharmaBiome receives the SME Instrument Phase I grant from the European Commission’s Horizon2020 programme. The highly competitive programme supports research and innovation in small and medium enterprises in a two step process and will advance the development of our lead compound.
The public was invited to vote for the venture-supported startups of the last 12 years and nominate the companies that have the potential to change the world. PharmaBiome is happy to announce to be the Global Shaper 2015 winner. https://www.venturekick.ch/Global-Shapers-12-companies-that-won-your-votes
PharmaBiome was included for the second year in a row in the list of the top 100 start ups in Switzerland. https://www.top100startup.ch